ACC.24 - Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA), and Principal Investigator, Dr Javed Butler (University of Mississippi Medical Center, US), as they discuss the key findings from the EMPACT-MI trial (Boehringer Ingelheim)(classic.clinicaltrials.gov/ct....
In this multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial, investigators evaluated the effect of empagliflozin, an SGLT2 inhibitor, on hospitalisation for heart failure (HF) and mortality in patients with acute myocardial infarction (MI).
The trial recruited 6522 participants, including eligible patients who presented with spontaneous MI alongside new signs or symptoms of pulmonary congestion requiring treatment, new left ventricular dysfunction (LVEF less than 45%), and at least one additional risk factor for the development of future HF. The primary outcome measure was the composite of time to first heart failure hospitalisation or all-cause mortality up to 26 months.
Findings, presented at ACC.24 showed that empagliflozin did not significantly reduce the risk of time to first HHF or all-cause death following AMI. Furthermore, empagliflozin demonstrated 23% and 33% relative risk reduction of first HHF and total HHF, components of the primary and first key secondary endpoints respectively.
Recorded remotely from Jackson and Hamilton, 2024.
Support: This is an independent content produced by Radcliffe Cardiology.
Editor: Mirjam Boros
Videographer: Mike Knight
Visit Radcliffe Cardiology: www.radcliffecardiology.com/
Visit Radcliffe Vascular: www.radcliffevascular.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: x.com/radcliffeCARDIO
25 июн 2024
